findmyKOL

Michael Morse, MD

Enriched profile

Professor of Medicine (Medical Oncology), Professor in the Department of Surgery · Duke University School of Medicine

ORCIDNPI
Region🇺🇸 Durham, NC · Southeast · United StatesSpecialtyHematology / OncologyFocusImmunotherapy and Immune Responses+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceverified 2026Payments2021–2025NIH funding2001–2008

Michael Morse is Professor of Medicine (Medical Oncology), Professor in the Department of Surgery at Duke University School of Medicine. OpenAlex indexes 552 publications with 28,410 citations (h-index 82); ClinicalTrials.gov lists 18 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Michael A. Morse, MD, is Professor of Medicine (Medical Oncology), Professor in the Department of Surgery at Duke University School of Medicine / Duke Cancer Institute. The public record shows 552 publications with 28,410 citations (h-index 82), centered on Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 33 companies, 3 NIH-funded awards (2001–2008).

  • Most recent indexed publication: 2025 · Science immunology
  • Top research focus: Immunotherapy and Immune Responses
  • 18 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 33 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Breast Cancer6 trialsColorectal Cancer5 trialsRectal Neoplasms4 trialsPancreatic Cancer3 trialsOvarian / Gynecologic Cancer2 trialsLung Cancer (NSCLC/SCLC)2 trialsColonic Neoplasms2 trialsGastroesophageal Cancer1 trialStomach Neoplasms1 trialHepatobiliary Cancer1 trialLiver Neoplasms1 trialProstate Cancer1 trialNeuroendocrine Tumors1 trialLeukemia (AML/ALL/CML/CLL)1 trialMDS / MPN1 trialLeukemia, Myeloid, Acute1 trialPrecursor Cell Lymphoblastic Leukemia-Lymphoma1 trialMelanoma1 trial

Research focus

OpenAlex concept fingerprint
Immunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesCAR-T cell therapy researchvaccines and immunoinformatics approaches

Drugs & molecules

across trials, industry payments and publications
LanreotideClinical trialsIndustry payments19Publications1Lenvimageneric · LenvatinibClinical trialsIndustry payments220PublicationsLonsurfgeneric · Tipiracil / trifluridineClinical trialsIndustry payments179Publications

Works with

trial sponsors and companies reporting payments
Eisai Inc.Clinical trialsIndustry payments220Exelixis Inc.Clinical trialsIndustry payments189Taiho Oncology, Inc.Clinical trialsIndustry payments179

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
552publications

Distinct works indexed by OpenAlex, matched via ORCID; 7 in PubMed.

28,410citations

Total citations across indexed works.

82h-index

Hirsch index (OpenAlex). i10-index 283.

Clinical & industry

trials, payments and federal funding
18clinical trials

Investigator role on registered studies.

View trials
33companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
3NIH grants · 2001–2008

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

33 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    49.3%
    Serotonin-3 Receptor Antagonist32.6%
    Ondansetron Hcl100%
    Part D21 patients
    Potassium supplement8.7%
    Potassium Chloride100%
    Part D<11 patients
  • Cancer & immunology

    35.5%
    Kinase inhibitor35.5%
    Imatinib Mesylate76%Cabometyx25%
    Part D<11 patients
  • Nervous system

    15.2%
    Phenothiazine15.2%
    Prochlorperazine Maleate100%
    Part D16 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

3 NIH research awards on record, funded 20012008 per NIH RePORTER. The latest:

Congress activity

Updated 27 Aug 2026

114 congress contributions (2004–2025) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

H. Kim Lyerly209Amy Hobeika104Takuya Osada91

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/michael-morse-md-dccc1472

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com

Mentions by others

where others cite or feature them
  • Other

    netrf.org/specialist/dr-michael-morse-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →netrf.org
  • Other

    onclive.com/authors/michael-morse-md-duke-cancer-institute

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MHS

    Duke University Medical Center

    2000
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org
  • Fellowship

    Hematology-Oncology, Duke University Medical Center

    1996
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org
  • Residency

    Internal Medicine, University of Washington Medical Center

    1993
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org
  • MD

    Yale University School of Medicine

    1990
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org
  • Board Certified

    Internal Medicine, American Board of Internal Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org
  • Board Certified

    Medical Oncology, American Board of Internal Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org
  • Board Certified

    Hematology, American Board of Internal Medicine

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →beattheboards.com
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu
  • Member

    Duke Cancer Institute

    1993
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.